{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:04:02Z","timestamp":1793127842313,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T00:00:00Z","timestamp":1414454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Previous studies have demonstrated that patients with psoriasis have higher rates of comorbidities compared to the general population. Despite the clinical and economic burden of psoriatic disease, there have been few large\u2010scale observational studies focused on this condition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess rates of cardiovascular, autoimmune, infectious and other conditions in patients with psoriasis or psoriatic arthritis (<jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The data for this retrospective study were obtained from the Clinical Practice Research Datalink (<jats:styled-content style=\"fixed-case\">CRPD<\/jats:styled-content>). Cohorts of patients with psoriasis (<jats:italic>n<\/jats:italic>\u00a0=\u00a027\u00a0672; mild, <jats:italic>n<\/jats:italic>\u00a0=\u00a022\u00a0174, severe, <jats:italic>n<\/jats:italic>\u00a0=\u00a05498) and <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content> (<jats:italic>n<\/jats:italic>\u00a0=\u00a01952) were generated based on the diagnosis made by general practitioner or specialist recorded in <jats:styled-content style=\"fixed-case\">CPRD<\/jats:styled-content> between 2006 and 2010. Frequencies of comorbidities at baseline and incidence rate ratios (<jats:styled-content style=\"fixed-case\">IRR<\/jats:styled-content>) of medical conditions occurring during follow\u2010up were calculated and compared between groups. Cox proportional hazard models were employed to compare hazard ratios (<jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content>) of comorbidities across the same subpopulations previously described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Significant differences in the unadjusted risk of cardiovascular disease, hyperlipidaemia, diabetes, skin cancer and autoimmune diseases were observed between patients with differing severity of psoriasis or between <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content> and psoriasis patients. The adjusted <jats:styled-content style=\"fixed-case\">HR<\/jats:styled-content> analyses confirmed patients with severe psoriasis had significantly higher rates of several conditions including diabetes (1.23; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 1.01\u20131.51) and rheumatoid arthritis (2.88; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 2.25\u20133.67) compared to patients with mild psoriasis. Patients with <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content> had significantly higher adjusted rates of hypertension (1.30; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 1.01\u20131.68), rheumatoid arthritis (6.93; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 5.45\u20138.80) and ankylosing spondylitis (6.98; 95% <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>: 2.37\u201320.58) compared to those with severe psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Patients with mild psoriasis are less affected by comorbid conditions than those with severe psoriasis, and patients with psoriasis are less affected by comorbidities than those with <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>. Given the differences observed across severities of psoriasis and between psoriasis and <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>, each patient subgroup should be taken into consideration in clinical practice and future research.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12742","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T02:45:21Z","timestamp":1414550721000},"page":"955-963","source":"Crossref","is-referenced-by-count":82,"title":["Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink"],"prefix":"10.1111","volume":"29","author":[{"given":"E.","family":"Edson\u2010Heredia","sequence":"first","affiliation":[{"name":"Eli Lilly and Company Indianapolis USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lefevre","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Erl Wood UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wang","sequence":"additional","affiliation":[{"name":"Evidera London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Erl Wood UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Bushe","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Erl Wood UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cox","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Erl Wood UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology Kaiser Permanente Los Angeles Medical Center Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Maeda\u2010Chubachi","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.12.1537"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032482"},{"issue":"6","key":"e_1_2_5_4_1","first-page":"S160","article-title":"Clinical features of psoriatic arthritis","volume":"8","author":"Krueger GC","year":"2002","journal-title":"Am J Manag Care"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262170-00004"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08779.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1493"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07986.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-006-0703-z"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000232302"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.14.1735"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.186"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta4400"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0366-077X.2004.05949.x"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.12.1582"},{"key":"e_1_2_5_17_1","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han C","year":"2006","journal-title":"J Rheumatol"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2006.09.001"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2008.01215.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401021"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-32"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.302.6779.766"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp567"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.08.040"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02936.x"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07562.x"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.94"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.04.039"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5015"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20627"},{"key":"e_1_2_5_33_1","volume-title":"Indicators for Monitoring Musculoskeletal Problems and Conditions. Musculoskeletal Problems and Functional Limitation","author":"European Commission","year":"2003"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12742","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T17:08:50Z","timestamp":1695575330000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,28]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/jdv.12742"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12742","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,28]]}}}